14 results
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
IgM and Non-IgM ... of Progression #EBM ... #Honc #MGUS #Progression ... #IgM #NonIgM #MultipleMyeloma ... #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Progression of MGUS ... Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM
Algorithm for the Evaluation of Anemia #Diagnosis #EM #IM #Honc #Anemia #Differential #Workup #Algorithm #Microcytic #Macrocytic
Anemia #Diagnosis #EM ... #IM #Honc #Anemia
Evaluation of Lymphadenopathy - Localized vs Generalized #Diagnosis #EM #IM #Honc #Lymphadenopathy #Localized #Generalized #Infectious #Malignancy
Generalized #Diagnosis #EM ... #IM #Honc #Lymphadenopathy
Common Causes of the Different Categories of Dizziness #Diagnosis #PrimaryCare #EM #IM #Differential #Dizziness #Vertigo #Disequilibrium
#PrimaryCare #EM ... #IM #Differential ... Lightheadedness #Table #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Hemolysis in Hereditary Spherocytosis. Panel A shows the structure of a normal red cell and a
Pathophysiology #Honc ... #IM #Spherocytosis ... HereditarySpherocytosis #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis - Incidence of New Vertebral, Clinical,
Nonvertebral Fracture #EBM ... PrimaryCare #Endo #IM ... #Alendronate #NEJM